SEPT9-i1 is required for the association between HIF-1α and importin-α to promote efficient nuclear translocation

Cell Cycle

Volumn 12, Issue 14, 2013, Pages 2297-2308

  Golan, Maya ^a   Mabjeesh, Nicola J ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

HIF 1 ; Importin ; Nuclear translocation; SEPT9 i1

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; KARYOPHERIN ALPHA; SEPTIN; SEPTIN 9; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CELL HYPOXIA; CELL LEVEL; CELL NUCLEUS; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; EMBRYO; FEMALE; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALE; NUCLEAR LOCALIZATION SIGNAL; NUCLEOTIDE SEQUENCE; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSACTIVATION; TRANSCRIPTION REGULATION; TUMOR VASCULARIZATION;

EID: 84880422242     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.25379     Document Type: Article

References (28)

1. Spiliotis ET, Gladfelter AS. Spatial guidance of cell asymmetry: septin GTPases show the way. Traffic 2012; 13:195-203; PMID:21883761; http://dx.doi.org/10.1111/j.1600-0854.2011.01268.x
2. Connolly D, Yang Z, Castaldi M, Simmons N, Oktay MH, Coniglio S, et al. Septin 9 isoform expression, localization and epigenetic changes during human and mouse breast cancer progression. Breast Cancer Res 2011; 13:R76; PMID:21831286; http://dx.doi.org/10.1186/bcr2924
3. Gonzalez ME, Peterson EA, Privette LM, Loffreda-Wren JL, Kalikin LM, Petty EM. High SEPT9-v1 expression in human breast cancer cells is associated with oncogenic phenotypes. Cancer Res 2007; 67:8554-64; PMID:17875694; http://dx.doi.org/10.1158/0008-5472.CAN-07-1474
4. Montagna C, Lyu MS, Hunter K, Lukes L, Lowther W, Reppert T, et al. The Septin 9 (MSF) gene is amplified and overexpressed in mouse mammary gland adenocarcinomas and human breast cancer cell lines. Cancer Res 2003; 63:2179-87; PMID:12727837 (Pubitemid 36538624)
5. Burrows JF, Chanduloy S, McIlhatton MA, Nagar H, Yeates K, Donaghy P, et al. Altered expression of the septin gene, SEPT9, in ovarian neoplasia. J Pathol 2003; 201:581-8; PMID:14648661; http://dx.doi.org/10.1002/path.1484 (Pubitemid 38256407)
6. Scott M, McCluggage WG, Hillan KJ, Hall PA, Russell SE. Altered patterns of transcription of the septin gene, SEPT9, in ovarian tumorigenesis. Int J Cancer 2006; 118:1325-9; PMID:16161048; http://dx.doi.org/10.1002/ijc.21486 (Pubitemid 43185625)
7. Bennett KL, Karpenko M, Lin MT, Claus R, Arab K, Dyckhoff G, et al. Frequently methylated tumor suppressor genes in head and neck squamous cell carcinoma. Cancer Res 2008; 68:4494-9; PMID:18559491; http://dx.doi.org/10.1158/ 0008-5472.CAN-07-6509
8. Stanbery L, D'Silva NJ, Lee JS, Bradford CR, Carey TE, Prince ME, et al. High SEPT9-v1 Expression Is Associated with Poor Clinical Outcomes in Head and Neck Squamous Cell Carcinoma. Transl Oncol 2010; 3:239-45; PMID:20689765
9. Amir S, Wang R, Matzkin H, Simons JW, Mabjeesh NJ. MSF-A interacts with hypoxia-inducible factor-1alpha and augments hypoxia-inducible factor transcriptional activation to affect tumorigenicity and angiogenesis. Cancer Res 2006; 66:856-66; PMID:16424018; http://dx.doi.org/10.1158/0008-5472.CAN-05-2738 (Pubitemid 43165951)
10. Podar K, Anderson KC. A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways. Cell Cycle 2010; 9:1722-8; PMID:20404562; http://dx.doi.org/10.4161/cc.9.9.11358
11. Cosse JP, Michiels C. Tumor hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem 2008; 8:790-7; PMID:18855580; http://dx.doi.org/10.2174/187152008785914798
12. Semenza GL. Hypoxia and cancer. Cancer Metastasis Rev 2007; 26:223-4; PMID:17404692; http://dx.doi.org/10.1007/s10555-007-9058-y (Pubitemid 47101662)
13. Semenza GL. Hypoxia and human disease-and the Journal of Molecular Medicine. J Mol Med (Berl) 2007; 85:1293-4; PMID:18026915; http://dx.doi.org/10. 1007/s00109-007-0285-z (Pubitemid 50004094)
14. Park EJ, Kong D, Fisher R, Cardellina J, Shoemaker RH, Melillo G. Targeting the PAS-A domain of HIF-1alpha for development of small molecule inhibitors of HIF-1. Cell Cycle 2006; 5:1847-53; PMID:16861921; http://dx.doi.org/10.4161/cc.5.16.3019 (Pubitemid 44435329)
15. Gardner LB, Corn PG. Hypoxic regulation of mRNA expression. Cell Cycle 2008; 7:1916-24; PMID:18604161; http://dx.doi.org/10.4161/cc.7.13.6203 (Pubitemid 352030334)
16. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010; 29:625-34; PMID:19946328; http://dx.doi.org/10.1038/onc.2009.441
17. Wilson IA, Haft DH, Getzoff ED, Tainer JA, Lerner RA, Brenner S. Identical short peptide sequences in unrelated proteins can have different conformations: a testing ground for theories of immune recognition. Proc Natl Acad Sci U S A 1985; 82:5255-9; PMID:2410917; http://dx.doi.org/10.1073/pnas.82. 16.5255 (Pubitemid 15012085)
18. Depping R, Steinhoff A, Schindler SG, Friedrich B, Fagerlund R, Metzen E, et al. Nuclear translocation of hypoxia-inducible factors (HIFs): involvement of the classical importin alpha/beta pathway. Biochim Biophys Acta 2008; 1783:394-404; PMID:18187047; http://dx.doi.org/10.1016/j.bbamcr.2007.12.006
19. Amir S, Golan M, Mabjeesh NJ. Targeted knockdown of SEPT9-v1 inhibits tumor growth and angiogenesis of human prostate cancer cells concomitant with disruption of hypoxia-inducible factor-1 pathway. Mol Cancer Res 2010; 8:643-52; PMID:20407014; http://dx.doi.org/10.1158/1541-7786.MCR-09-0497
20. Amir S, Wang R, Simons JW, Mabjeesh NJ. SEPT9-v1 up-regulates hypoxia-inducible factor 1 by preventing its RACK1-mediated degradation. J Biol Chem 2009; 284:11142-51; PMID:19251694; http://dx.doi.org/10.1074/jbc.M808348200
21. Sellin ME, Stenmark S, Gullberg M. Mammalian SEPT9 isoforms direct microtubule-dependent arrangements of septin core heteromers. Mol Biol Cell 2012; 23:4242-55; PMID:22956766; http://dx.doi.org/10.1091/mbc.E12-06-0486
22. Kinoshita M. Assembly of mammalian septins. J Biochem 2003; 134:491-6; PMID:14607974; http://dx.doi.org/10.1093/jb/mvg182 (Pubitemid 37442871)
23. Luo JC, Shibuya M. A variant of nuclear localization signal of bipartite-type is required for the nuclear translocation of hypoxia inducible factors (1alpha, 2alpha and 3alpha). Oncogene 2001; 20:1435-44; PMID:11313887; http://dx.doi.org/10.1038/sj.onc.1204228 (Pubitemid 32291194)
24. Chachami G, Paraskeva E, Mingot JM, Braliou GG, Görlich D, Simos G. Transport of hypoxia-inducible factor HIF-1alpha into the nucleus involves importins 4 and 7. Biochem Biophys Res Commun 2009; 390:235-40; PMID:19788888; http://dx.doi.org/10.1016/j.bbrc.2009.09.093
25. Manisterski M, Golan M, Amir S, Weisman Y, Mabjeesh NJ. Hypoxia induces PTHrP gene transcription in human cancer cells through the HIF-2α. Cell Cycle 2010; 9:3723-9; PMID:20890122; http://dx.doi.org/10.4161/cc.9.18.12931
26. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003; 3:363-75; PMID:12726862; http://dx.doi.org/10.1016/S1535-6108(03)00077-1 (Pubitemid 38340305)
27. Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW, et al. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002; 62:2478-82; PMID:11980636 (Pubitemid 34462721)
28. Ben-Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y, Mabjeesh NJ. 1alpha,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther 2007; 6:1433-9; PMID:17431122; http://dx.doi.org/10.1158/1535-7163. MCT-06-0677 (Pubitemid 46712007)